baber/WOPTO huggingface dataset:
Patent NZ-221620-A (NZ)
Title: Producing wood fibre boards: wood dust coating before pressing and polishing
Inventor: KUNNEMEYER OTTO
IPC: B27N3/10
Filed: 1987-08-31
Abstract: There is proposed a process for the manufacture of wood fiber boards, wherein by far the largest part of the outer layers to be conventionally sanded away no longer consists of wood fibers but of wood dusts of a defined particle size, a material which is available as waste from other consolidations of wood raw materials. By employing the process of the invention, it also is possible to achieve an only small density drop towards the center of the board, so that this process is particularly suitable for the manufacture of medium density wood fiber boards with a weight of 600 to 950 kg/m3.
Patent NZ-226107-A (NZ)
Title: Maleic anhydride/1-alkene polymers having from 55-95 mole percent maleic anhydride
Inventor: BILLMAN FRED L
IPC: C08F222/06
Filed: 1988-09-09
Abstract: The present invention provides for a composition of matter characterized by comprising a free-radical addition polymer containing at least 55 to about 95 mole percent of units derived from maleic anhydride and from about 5 to 45 mole percent of units derived from at least one 1-alkene having at least 4 to 30+ carbon atoms wherein the polymer has an average of at least one unit derived from a 1-alkene per polymer chain based on the number average molecular weight of the polymer and wherein the maleic anhydride units are substantially randomly distributed throughout the polymer chains making up said polymer. The polymers are useful in detergents as stabilizers, additives in floor polishes and, especially when esterified with alcohols, as surfactants.
Patent NZ-231984-A (NZ)
Title: Immunoglobulins specifically reactive with il-2 receptor protein
Inventor: QUEEN CARY L
IPC: C07K16/46
Filed: 1990-01-04
Abstract: Compsn. comprises a pure human-like immunoglobulin (Ig) which (a) reacts specifically with p55 Tac protein and/or (b) inhibits binding of human interleukin-2 (IL-2) to its receptor. Also new are (1) human-like Ig having 2 pairs of light/heavy chains and able to react specifically with an epitope of a human IL-2 receptor with affinity at least 10 power 8 per mole, the chains including complementarily determg. regions (CDR's) and human-like framework regions (FR's), the CDR's being from different Ig molecules than FR's; (2) humanised Ig (hIg) which can bind to IL-2 receptors and contain at least one CDR from anti-Tac antibody in a human-like FR contg. at least one amino acid from the anti-Tac antibody; (3) nucleic acid encoding for human-like FR and at least one murine CDR, and (4) cells transfected with nucleic acid.
Patent NZ-232781-A (NZ)
Title: Endless papermakers fabric with oblique seam
Inventor: WASYLEZUCK MICHEL
IPC: F16G3/04
Filed: 1990-03-05
Abstract: PCT No. PCT/GB90/00332 Sec. 371 Date Aug. 29, 1991 Sec. 102(e) Date Aug. 29, 1991 PCT Filed Mar. 5, 1990 PCT Pub. No. WO90/10165 PCT Pub. Date Sep. 7, 1990.A papermakers fabric, and particularly a corrugator fabric, has a flat-woven, multilayer structure and is brought into endless form by a joint or seam arranged obliquely relative to the running direction of the fabric and at the roller side thereof. The angular disposition of the seam reduces noise levels, sheet marking and web breakage.
Patent NZ-234144-A (NZ)
Title: Wireless animal controller: receiver has plural antennae
Inventor: GIUNTA JAMES M
IPC: A01K15/02
Filed: 1990-06-19
Abstract: A system for controlling the movement of an animal relative to an area is provided having a signal transmitter with a transmitting antenna associated with said area. A loop of wire serves as the transmitting antenna and defines the boundary of the area. An electronic receiver carried by the animal is responsive to a signal produced by the transmitting antenna for producing an animal control output, such as an annoying tone or an electrical shock, to the animal whenever the animal moves into the vicinity of the transmitting antenna. The electronic receiver has first and second orthogonal receiving antennas for receiving the signal produced by the wire loop antenna. Each antenna receives a respective component of the transmitted signal. Selection circuitry selects which of the respective components has greater magnitude and produces an actuating output to identify such component. Switch circuitry receives the respective components of the transmitted signal from each of the respective receiving antennas. The switch circuitry responds to the actuating output produced by the selection circuitry to output the respective component having greater magnitude. Control circuitry is responsive to the selected component output from the switch circuit for producing the control output to the animal to control the movement of the animal relative to the selected area. As such, the control circuitry continuously responds to the receiving antenna having the best reception to produce the animal control output.
Patent NZ-236627-A (NZ)
Title: A dispensing device for delivering a beneficial agent to an environment of use continuously for an extended period of time
Inventor: AYER ATUL DEVDATT
IPC: A61K9/22
Filed: 1990-12-21
Abstract: PCT No. PCT/US90/07598 Sec. 371 Date Jun. 2, 1992 Sec. 102(e) Date Jun. 2, 1992 PCT Filed Dec. 21, 1990 PCT Pub. No. WO91/10423 PCT Pub. Date Jul. 10, 1991The invention provides a dispensing device (10) comprising a loading dose (32) (first agent delivery device) for short-term and continuous delivery of agent, retained together with a long-term dispensing device (12) (second agent delivery device) capable of long-term and continuous delivery of agent. The combination of first and second agent delivery device provides a device in which a substantially constant dose of beneficial agent is delivered to the environment of use over time. A rapid delivery of beneficial agent is followed by continuous and prolonged delivery of agent. In a preferred embodiment the device includes (A) a loading dose chamber (30) and retaining device (16) retaining a loading dose (32) (short-term delivery device) for rapid and continuous delivery of agent to the environment of use; and (B) a long-term dispensing device (12) (long-term delivery device) comprising a semipermeable wall (14) which surrounds and defines an internal lumen (20), a driving source (22) (expansion device) in the lumen for expanding and occupying an increased volume of the lumen, a beneficial agent (24) in the lumen that provides a dispensable formulation to the environment of use, and an exit (28) in the device for delivery of the beneficial agent to the environment of use over time. A densifier (26) and/or a moveable barrier device (34) may also be included in the lumen of the long-term dispensing device.
Patent NZ-238184-A (NZ)
Title: 3-(4-(1-(1h-indazol-3-yl)-4-piperazinyl)-butyl)-4-thiazolidinone derivatives; preparatory processes and pharmaceutical compositions
Inventor: HRIB NICHOLAS J
IPC: A61P25/18
Filed: 1991-05-17
Abstract: This invention relates to 3-[1-thiazolidinylbutyl-4-piperazinyl]-1H-indazoles of the formula I <CHEM> where R1 and R2 are each independently hydrogen or loweralkyl or R1 and R2 taken together with the carbon atom to which they are attached form a cyclopentane, cyclohexane or cycloheptane ring; R3 ad R4 are independently hydrogen or loweralkyl or R3 and R4 taken together with the carbon atom to which they are attached form a cyclopentane, cyclohexane or cycloheptane ring; R5 is hydrogen, loweralkyl, alkanoyl or aroyl; X is halogen, loweralkyl or alkoxy; m is an integer of 0 to 3, the pharmaceutically acceptable acid addition salts thereof and where applicable, the optical, geometrical and stereoisomers and racemic mixtures thereof. The compounds of this invention are useful as antipsychotic agents.
Patent NZ-248703-A (NZ)
Title: Certain 3-methylsulphonyl benzoylguanidine compounds and their medical use
Inventor: LANG HANS-JOCHEN
IPC: C07D211/14
Filed: 1993-09-20
Abstract: The invention relates to benzoylguanidines of the formula I <IMAGE> where R(1) or R(2) is equal to R(3)-S(O)n- or R(4)R(5)N-O2S- and the other substituent R(1) or R(2) is in each case equal to H, OH, F, Cl, Br, I, alkyl, alkoxy, benzyloxy or phenoxy, R(3)-S(O)n or R(4)R(5)N- or 3,4-dehydropiperidine and R(3) is equal to alkyl, cycloalkyl, cyclopentylmethyl, cyclohexylmethyl or phenyl, R(4) and R(5) are equal to alkyl or phenylalkyl or phenyl, and in which R(4) and R(5) together can also be a C4-C7-chain, and in which R(4) and R(5), together with the nitrogen atom to which they are bonded, can denote a dihydroindol, tetrahydroquinoline or tetrahydroisoquinoline system,  and where n is equal to zero, 1 or 2 and their pharmaceutically tolerable salts are outstanding antiarrhythmic agents. They are obtained by a process in which compounds of the formula II <IMAGE> in which X stands for a leaving group which can be easily nucleophilically substituted, are reacted with guanidine.
Patent NZ-248862-A (NZ)
Title: Corrosion preventative for aqueous systems comprising orthophosphate, an azole, polyepoxysuccinc acid and a copolymer of acrylic acid and allyl hydroxypropyl sulphonate ether
Inventor: KESSLER STEPHEN M
IPC: C23F11/08
Filed: 1993-10-05
Abstract: A low phosphorus process for controlling corrosion in aqueous systems is described which involves adding to the aqueous system an effective amount of a composition comprising orthophosphate, azole, polyepoxysuccinic acid and the copolymer of acrylic acid and allyl hydroxypropyl sulfonate ether.
Patent NZ-253145-A (NZ)
Title: Adhesive and sealant compositions comprising a liquid reactive prepolymer and an at least partly incompatible solid component
Inventor: PROEBSTER MANFRED
IPC: C09J175/04
Filed: 1993-06-21
Abstract: Adhesives and sealants (I) are claimed, contg. (a) reactive prepolymer(s) which is/are liq. at room temp. and (b) other component(s) which is/are solid at room temp., liq. at a slightly higher temp. and at least partly incompatible with (a). Also claimed is a process for the prodn. of (I) by compounding at a temp. above the m.pt. of component (b).
Patent NZ-264633-A (NZ)
Title: The phosphoric acid salt of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propa namine and its preparation
Inventor: BERGLUND RICHARD ALLAN
IPC: C07C63/08
Filed: 1994-10-06
Abstract: Prepn. of S-(+)-N,N-dimethyl-3-(1-naphthyloxy)-3-(2- thienyl)-propanamine (I) comprises reacting (S)-(-)-N,N- dimethyl-3-(2-thienyl)-3-hydroxy-propanamine (II) with sodium hydride, potassium benzoate or acetate and 1-fluoro-naphthalene (III) in an organic solvent. (II) and NaH are dissolved in the solvent, the potassium cpd. is added with stirring, then (III) is added with stirring. (I) is isolated as the phosphoric acid salt. Typically the solvent is DMSO, the use amt. of NaH is 1 equiv/equiv. (II), the use amt. of potassium cpd. is 0.05-1 equiv./equiv. (II) and stirring is at 10-35 [deg] C for 5-60 min. Use amt. of (III) is 1-25% excess and stirring is at 40-75 [deg] C for 1.5-4 hrs.
Patent NZ-271435-A (NZ)
Title: Renovation of synthetic grass surfaces by removal of particulate matter with compressed air plenum and nozzles reciprocated transversely to travel direction
Inventor: LAWRENCE CHARLES CLIFFORD SEAG
IPC: E01H1/08
Filed: 1994-09-01
Abstract: PCT No. PCT/GB94/01898 Sec. 371 Date Feb. 29, 1996 Sec. 102(e) Date Feb. 29, 1996 PCT Filed Sep. 1, 1994 PCT Pub. No. WO95/06781 PCT Pub. Date Mar. 9, 1995An apparatus (5) for renovating synthetic grass playing surfaces (1) which include a layer of particulate material. The apparatus (5) comprises a plenum chamber (20) which directs a fast moving jet of air against the particulate so as to dislodge it and direct the particulate into a collection chamber (40). The plenum chamber (20) may be adapted to effect a reciprocating motion parallel to a playing surface (1) and orthogonal to a direction of conveyance of the apparatus (5) over the playing surface (1). The collection chamber (20) may incorporate a screw conveyor system (44) to displace particulate material directed into the collection chamber (20) to an appropriate container which may be conveyed along side the apparatus (5) by a separate vehicle. The apparatus (5) may further include a particulate dispensing apparatus for applying an evenly spread layer of fresh particulate material in place of that which has been dislodged and removed from the playing surface (1).
Patent NZ-285450-A (NZ)
Title: Stabilising solutions of duocarmycin derivatives by adding saccharide, electrolyte, water-soluble polymer, polyhydric alcohol and/or surfactant
Inventor: NAKAKURA MASASHI
IPC: A61K9/19
Filed: 1995-05-19
Abstract: PCT No. PCT/JP95/00962 Sec. 371 Date Oct. 30, 1996 Sec. 102(e) Date Oct. 30, 1996 PCT Filed May 19, 1995 PCT Pub. No. WO95/31971 PCT Pub. Date Nov. 30, 1995Stabilized duocarmycin derivatives represented by formula (I):    <IMAGE>  (I)   <IMAGE>   wherein R is lower alkyl, allyl or benzyl, and X is Cl or Br, are prepared by adding at least a compound selected from the group consisting of a saccharide, an electrolyte, a water-soluble polymer, a polyhydric alcohol and a surfactant to a solution containing the duocarmycin derivatives. Also provided are freeze-dried pharmaceutical preparations containing the stabilized duocarmycin derivatives.
Patent NZ-331669-A (NZ)
Title: Propofol microdroplet formulations Propofol microdroplet formulations
Inventor: HAYNES DUNCAN H HAYNES DUNCAN
IPC: A61P23/00
Filed: 1997-03-17
Abstract: ormulations of phospholipid-coated microdroplets of propofol devoid of fats and triglycerides provide chronic sedation over extended periods of time without fat overload. Being free of nutrients that support bacterial growth, these microdroplet formulations are bacteriostatic and bactericidal (e.g. self-sterilizing) and thus have extended shelf life.
Patent NZ-332345-A (NZ)
Title: Thermostable xylanases isolated from Microtetraspora
Inventor: BODIE ELISABETH A
IPC: C12P21/00
Filed: 1998-10-15
Abstract: Disclosed are xylanases isolated form the genus Microtetraspora which are useful in methods of delignification and/or bleaching of pulp.
Patent NZ-332565-A (NZ)
Title: Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
Inventor: SMITH DOUGLAS
IPC: C12Q1/68
Filed: 1997-03-27
Abstract: Recombinant or substantially pure preparations of H. pylori polypeptides are described.  The nucleic acids encoding the polypeptides also are described.  The H. pylori polypeptides are said to be useful in diagnostic and vaccine compositions.
Patent NZ-500986-A (NZ)
Title: Dissolving oxygen-containing gas in a volume of liquid having an oxygen demand
Inventor: HANSON CEDRIC
IPC: B01F5/02
Filed: 1999-11-11
Abstract: An apparatus for dissolving oxygen containing gas in a volume of liquid having an oxygen demand comprises a pump 2, a main conduit 4 and a plurality of first and second subsidiary conduits 6A, 6B in communication with main conduit 4.  Each of the conduits include a configuration to create turbulence in the flowing liquid.  There is a means for introducing gas into the turbulence and a nozzle 12 which terminates in the volume of the liquid which has an outlet configured such that the liquid is introduced into the volume of liquid at a velocity sufficient to create further turbulence and means for sensing the oxygen demand in the volume of liquid.  The gas introducing mean in the first and second subsidiary conduits 6A, 6B are adapted for introducing oxygen and air respectively and control means 15 which is responsive to the sensed oxygen demand, are provided to vary the relative proportions of oxygen and air introduced.
Patent NZ-501966-A (NZ)
Title: Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders
Inventor: CAVAZZA CLAUDIO
IPC: A61K31/205
Filed: 1998-07-08
Abstract: L-carnitine or an alkanoyl L-carnitine selected from acetyl, propionyl, butyryl, valeryl and isovaleryl L-carnitine or a pharmacologically acceptable salt thereof may be used in a therapeutical method for the treatment of Attention-Deficit/Hyperactive Disorder (ADHD). The medicament is an oral or parenterally administrable composition that may be administered to a child affected by ADHD in an amount administered per day from 30 to 120 mg of L-carnitine, or a molar equivalent amount of alkanoyl L-carnitine, per kilogram of body weight. The pharmacologically acceptable salt of L-carnitine or alkanoyl L-carnitine is selected from chloride, bromide, orotate, aspartate, acid aspartate, acid tartrate, acid citrate, acid phosphate, fumarate, acid fumarate, lactate, maleate, acid maleate, acid oxalate, acid sulphate, glucose phosphate, and tartrate.
Patent NZ-502195-A (NZ)
Title: Production of oxalate secreting pathogen resistant plants
Inventor: GLEN S
IPC: C12N15/82
Filed: 1998-07-16
Abstract: A method of increasing a plant's resistance to an oxalate-secreting pathogen comprises: a) crossing a transgenic plant containing an oxalate oxidase or oxalate decarboxylase gene with an oxalate-secreting pathogen tolerant plant and expressing the oxalate oxidase or oxalate decarboxylase gene thereby making the plant more resistance to an oxalate-secreting pathogen or b) transforming a plant or plant tissue with oxalate oxidase or oxalate decarboxylase gene wherein the plant tissue has an oxalate-secreting pathogen tolerant genetic background and expressing the oxalate oxidase or oxalate decarboxylase gene thereby making the plant more resistance to an oxalate-secreting pathogen or c) introducing an oxalate oxidase or oxalate decarboxylase gene into the genome of a plant which is tolerant to an oxalate-secreting pathogen and expressing the oxalate oxidase or oxalate decarboxylase gene thereby making the plant more resistance to an oxalate-secreting pathogen. The plant can be sunflower, alfalfa, soybean, sorghum, maize, wheat or rice and the pathogen can be a fungal pathogen such as Sclerotinia.
Patent NZ-504245-A (NZ)
Title: Prodrugs of thrombin inhibitors
Inventor: ANTONSSON THOMAS
IPC: C12N9/99
Filed: 1996-12-17
Abstract: A method of treatment of a condition where inhibition of thrombin is required, where the method comprises administration of a therapeutically effective amount of a compound of formula I:  R1O(O)C-H2-(R)Cgl-Aze-Pab-R2 And the variables in formula I are described in the specification. The condition to be treated may be thrombosis, hypercoagulability in blood and tissues, Alzheimer's disease, idiopathic and adult respiratory distress syndrome and pancreatitis. (62) Divided out of 324902
Patent NZ-505874-A (NZ)
Title: Cycloalkene derivatives for inhibiting nitric oxide and/or cytokine production
Inventor: ICHIMORI YUZO
IPC: A61K31/18
Filed: 1999-03-08
Abstract: A  compound represented by the formula I. R represents an    aliphatic   hydrocarbon   group   optionally    having substituents,  an  aromatic  hydrocarbon  group   optionally having  substituents, a heterocyclic group optionally having substituents,  a  group represented  by  the  formula:  OR-1 (wherein  R1  represents a hydrogen  atom  or  an  aliphatic hydrocarbon group optionally having substituents) or a group represented by the formula II. R1b  represents a hydrogen atom or an aliphatic  hydrocarbon group  optionally having substituents, R1c is, same with  or different   from  R1b,  a  hydrogen  atom  or  an  aliphatic hydrocarbon   group  optionally  having  substituents.    R0 represents  a  hydrogen  atom or  an  aliphatic  hydrocarbon group.  Alternatively, R and R0 represent a bond  with  each other,  ring  A  is  a cycloalkene substituted  by  1  to  4 selected from: (i)   an   aliphatic  hydrocarbon  group  optionally  having substituents, (ii)   an  aromatic  hydrocarbon  group  optionally   having substituents, (iii)  a  group represented by the formula: OR1 (wherein  R1 represents the same meaning as mentioned above) and (iv)  a  halogen atom, Ar represents an aromatic hydrocarbon group optionally having substituents, a group represented by the  formula,  where n is an integer of 1 to 4,  or  a  salt thereof.
Patent NZ-510951-A (NZ)
Title: Device for dispersal of fluidized powder
Inventor: SUN HOI CHEONG
IPC: B02C23/08
Filed: 1999-10-14
Abstract: Provided is, among other things, and together with associated methods, a powder feed apparatus including a venturi (120) with an external gas inlet, a gas outlet, and an internal gas inlet, a cyclone (130) with an intake port connected to the gas outlet, a recycle outlet port, and a product port.
Patent NZ-519380-A (NZ)
Title: Heterocyclic compounds having sulfonamide groups
Inventor: HANEDA TORU
IPC: C07D217/22
Filed: 2000-12-27
Abstract: Heterocyclic compounds having sulfonamide or sulfonylurea groups, specifically heterocyclic compounds of formula (I), pharmacologically acceptable salts of the same, or hydrates of both are disclosed, wherein A is hydrogen, halogen, optionally halogenated C1-4 alkyl, or as defined in the specification; B is optionally substituted aryl, monocyclic heteroaryl, or as defined in the specification; K is a single bond or as defined in the specification; T, W, X and Y are each independently =C(D) - (wherein D is hydrogen, halogen, or as defined in the specification) or nitrogen; U and V are each independently =C(D) -, nitrogen, oxygen, or -CO-; Z is a single bond; and R1 is hydrogen. These compounds are suitable for producing antiangiogenic agents that are useful as medicaments for treating diseases such as cancer, diabetes retinopathy, rheumatic arthritis, hematoma, etc.
Patent NZ-519466-A (NZ)
Title: Sustained-release formulation of a cyclooxygenase-2 inhibitor
Inventor: HEDDEN DAVID B
IPC: A61K9/22
Filed: 2000-12-20
Abstract: An orally deliverable pharmaceutical composition comprising a therapeutically effective amount of a selective cyclooxygenase-2 inhibitory drug of low water solubility and one or more pharmaceutically acceptable polymers, wherein the composition provides an in vitro sustained-release dissolution profile following placement in a standard dissolution medium exhibiting (a) release of about 5% to about 35% of the drug 2 hours after said placement; (b) release of about 10% to about 85% of the drug 8 hours after said placement; and (c) release of about 30% to about 90% of the drug 18 hours after said placement.
Patent NZ-519971-A (NZ)
Title: Purine derivatives
Inventor: MANTELL SIMON JOHN
IPC: A61P9/12
Filed: 2001-02-09
Abstract: Described are purine compounds of formula (I), for which the substituents are defined herein, also described is a process for preparing the compounds. The compounds are used in the manufacture of medicaments for the treatment of diseases mediated by adenosine A2a receptor agonists such as inflammation.
Patent NZ-523031-A (NZ)
Title: Satellite-based positioning system receiver for weak signal operation
Inventor: BRYANT RODERICK
IPC: G01S1/00
Filed: 2001-05-07
Abstract: A method, device and system for determining a receiver location using weak signal satellite transmissions. The invention involves a sequence of exchanges between an aiding source and a receiver that serve to provide aiding information to the receiver so that the receiver's location may be determined in the presence of weak satellite transmissions. With the aiding information, the receiver detects, acquires and tracks weak satellite signals and computes position solutions from calculated pseudo ranges despite the inability to extract time synchronization date from the weak satellite signals.
Patent NZ-525923-A (NZ)
Title: Methods of producing oxazolidinone compounds
Inventor: PERRAULT WILLIAM R
IPC: C07D413/10
Filed: 2001-10-17
Abstract: Methods of synthesizing pharmacologically useful oxazolidinones of formula (I), and the intermediate compounds are disclosed, wherein the variables are as defined in the specification. Particularly described is a method of manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol.